Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
09.09.2024 13:04:53
|
Lilly Names Lucas Montarce EVP And CFO With Immediate Effect
(RTTNews) - Drugmaker Eli Lilly and Co. (LLY) announced Monday the appointment of Lucas Montarce as executive vice president and chief financial officer and member of the company's Executive Committee, effective immediately.
Montarce succeeds Anat Ashkenazi, who resigned in June as CFO, to pursue a career opportunity outside of the pharmaceutical industry.
The new CFO, who joined Lilly in 2001, most recently served in the role of Lilly president and general manager for the Spain, Portugal and Greece hub. Previously, Montarce has held a range of finance leadership roles, including group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health.
David Ricks, chair and CEO, said, "Developing leadership talent has always been a strength for Lilly, and Lucas has thrived in a wide variety of roles of increasing scope and impact. Having worked directly with Lucas for more than a decade, I am highly confident he has the drive, curiosity and integrity to excel as our next CFO."
In pre-market activity on the NYSE, Lilly shares were trading at $912.89, up 1.13 percent.
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
25.07.25 |
Eli Lilly-Aktie wenig bewegt: EMA spricht sich für Zulassung von weiterem Alzheimer-Medikament aus (dpa-AFX) | |
22.07.25 |
S&P 500-Titel Eli Lilly-Aktie: So viel hätten Anleger an einem Eli Lilly-Investment von vor einem Jahr verloren (finanzen.at) | |
15.07.25 |
S&P 500-Titel Eli Lilly-Aktie: So viel Gewinn hätte ein Investment in Eli Lilly von vor 10 Jahren eingebracht (finanzen.at) | |
08.07.25 |
S&P 500-Papier Eli Lilly-Aktie: So viel Gewinn hätte ein Investment in Eli Lilly von vor 5 Jahren eingebracht (finanzen.at) | |
01.07.25 |
S&P 500-Wert Eli Lilly-Aktie: So viel Gewinn hätte ein Eli Lilly-Investment von vor 3 Jahren abgeworfen (finanzen.at) | |
24.06.25 |
S&P 500-Wert Eli Lilly-Aktie: So viel Verlust hätte eine Eli Lilly-Investition von vor einem Jahr eingebracht (finanzen.at) | |
20.06.25 |
Schwacher Wochentag in New York: S&P 500 in Rot (finanzen.at) | |
20.06.25 |
Handel in New York: S&P 500 zum Handelsstart mit Zuschlägen (finanzen.at) |
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 665,00 | 0,06% |
|